MiNK Therapeutics' MiNK's AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene

MiNK Therapeutics, Inc. -1.98%

MiNK Therapeutics, Inc.

INKT

0.99

-1.98%

MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced the publication of a case report in Oncogene from its phase 1/2 study in patients with advanced solid tumors where one infusion of agenT-797 in gastric cancer refractory to anti-PD1 led to a durable confirmed partial response, highlighting the unique potential of iNKT cells to overcome resistance to immune checkpoint inhibitors (ICIs).
 

Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via